Macular atrophy after combined intravitreal triamcinolone and photodynamic therapy to treat choroidal neovascularization

International Journal of Ophthalmology

Volumn 3, Issue 2, 2010, Pages 161-163

  Ruiz Moreno, José M ^a,b   Montero, Javier A ^b,c   Amat, Pedro ^b   Lugo, Francisco ^b  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^b Vitreo Retinal Unit   (Spain)

^c HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

Author keywords

Age related macular degeneration; Choriocapillaris atrophy; Intravitreous triamcinolone; Photodynamic therapy; Retinal pigment epitheliumatrophy

Indexed keywords

EID: 84880583071     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2010.02.16     Document Type: Article

References (19)

1. Jonas JB, SofkerA. Intraocular injection of crystalline cortisone as adjunctivetreatment of diabetic macular edema. Am JOphthalmol. 2001;132(3): 425-427. [PubMed]
2. Boscia F, FurinoC, DammaccoR, Ferreri P, Sborgia L, Sborgia C. Intravitreal triamcinoloneacetonidein refractory pseudophakic cystoid macular edema: functional andanatomic results. Eur J Ophthalmol. 2005;15(1): 89-95. [PubMed]
3. Degenring RF, Jonas JB. Intravitreal injection oftriamcinolone acetonide as treatment for chronic uveitis. Br J Ophthalmol. 2003;87: 361. [PMCfree article] [PubMed]
4. Gillies MC, Simpson JM, LuoW, Penfold P, Hunyor AB, Chua W, Mitchell P, Billson F. A randomizedclinical trial ofa single dose ofintravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003: 121(5): 667-673. [PubMed]
5. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combinedwith intravitreal triamcinolone in all types of choroidal neovascularization duetoage-related macular degeneration. Ophthalmology. 2006;113(1): 14-22. [PubMed]
6. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment ofintraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res. 2005;24(5): 587-611. [PubMed]
7. Ruiz-MorenoJM, MonteroJA, Zarbin MA. Photodynamictherapy and high-dose intravitreal triamcinolone totreat exudative age-related macular degeneration: 2-year outcome. Retina. 2007;27(4): 458-4b1. [PubMed]
8. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112(2): 301-304. [PubMed]
9. Luttrull JK, SpinkC.J. Prolongation of choroidal hypofluorescence following combinedverteporfin photodynamic therapy and intravitreal triamcinolone acetonide injection. Retina. 2007;27(6): 688-692. [PubMed]
10. Ruiz-MorenoJM, MonteroJA, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolonetotreat exudative age-related macular degeneration: 2-year outcome. Retina. 2007;27(4): 458-461. [PubMed]
11. Ranson NT, Danis RP, Ciulla TA, Pratt L. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol. 2002;86(5): 527-529. [PMCfree article] [PubMed]
12. Danis RP, Ciulla TA, Pratt LM,Anliker W. Intravitreal triamcinolone acetonide in exudative age-relatedmacular degeneration. Retina. 200203)244-250. [PubMed]
13. Postelmans L, Pasteels B, Coquelet P, El Ouardighi H,Verougstraete C, Schmidt-Erfurth U. Severe pigment epithelial alterations in the treatment area following photodynamictherapy for classic choroidal neovascularization in young females. Am JOphthalmol. 2004;138(5): 803-808. [PubMed]
14. Wachtlin J, BehmeT, Heimann H, Kellner U, Foerster MH. Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefes Arch din Exp Ophthalmol. 2003;241(6): 518-521. [PubMed]
15. Modarres M, Parvaresh MM, Peyman GA. Accidental subretinal injection oftriamcinolone acetonide. Ophthalmic Surg Lasers. 1998;29(11): 935-938. [PubMed]
16. Sutter FK, Kurz-Levin MM, Fleischhauer J, Bosch MM, Barthelmes D, Helbig H. Macular atrophy after combined intravitreal triamcinolone acetonide (IVTA) andphotodynamictherapy (PDT) for retinal angiomatous proliferation (RAP) Klin Monatsbl Augenheilkd. 2006;223(5): 376-378. [PubMed]
17. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, BeckendorfA, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derivedfactor. Invest Ophthalmol Vis Sci. 2003;44(10): 4473-4480. [PubMed]
18. Kim 1K, Husain D, MichaudN, Connolly E, LaneAM, Durrani K, Hafezi-Moghadam A, Gragoudas ES, O'Neill CA, Beyer JC, Miller JW. Effect ofintravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest Ophthalmol Vis Sci. 2006;47(1): 357-363. [PubMed]
19. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY, FOCUS Study Group Ranibizumab combinedwith verteporfin photodynamictherapy in neovascular age-relatedmacular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol. 2006;124(11): 1532-1542. [PubMed]